Carpenter D, Esterling K, Lazer D. “Friends Brokers and Transitivity: Who Talks with Whom in Washington Lobbying?” . Journal of Politics . 2004;66(1):224-246.

Carpenter D, Fendrick MA, Chernew M, Smith D. “Approval Times for New Drugs: Does the Source of Funding for FDA Staff Matter?” . Health Affairs – Web Exclusive. 2004;W3- 618-624.

Carpenter D. “The Political Economy of FDA Drug Approval: Processing Politics and Implications for Policy” . Health Affairs. 2004;23(1):52-63.

Carpenter D, Fendrick MA. “Accelerating Approval Times for New Drugs in the U.S”. The Regulatory Affairs Journal – Pharma. 2004;15(6):411-417.

Carpenter D. “Staff Resources Speed FDA Drug Review” . Journal of Health Policy Politics and Law. 2004;29(3):431-442.

Carpenter D, Lewis D. “Political Learning from Rare Events: Poisson Inference Fiscal Constraints and the Lifetime of Bureaus” . Political Analysis. 2004;12(3):201-232.

Carpenter D. “Gatekeeping and the FDA’s Role in Human Subjects Protection” . Virtual Mentor [American Medical Association] . 2004;6.

Carpenter D. “Protection without Capture: Product Approval by a Politically Responsive Learning Regulator”. American Political Science Review . 2004;98(4):613-631.